1. Andexanet alfa precautions revised due to heparin interaction

   News item 13 April 2024 Pages: 1 - 1

2. Calcium channel blockers may increase risk of eczema

   News item 13 April 2024 Pages: 2 - 2

3. Compounded semaglutide product substandard

   News item 13 April 2024 Pages: 3 - 3

4. COVID-19 vaccines do not increase GP visits for menstrual disorders

   News item 13 April 2024 Pages: 4 - 4

5. FDA final guidance on ICSRs from IND-exempt BA/BE studies

   News item 13 April 2024 Pages: 5 - 5

6. Medsafe warns against use of two moisturising creams

   News item 13 April 2024 Pages: 6 - 6

7. Moderna COVID-19 vaccine may cause chronic urticaria

   News item 13 April 2024 Pages: 7 - 7

8. Palbociclib (Ibrance): risk of venous thromboembolism

   Media release 13 April 2024 Pages: 8 - 8

9. Unauthorised skin products pose health risks

   News item 13 April 2024 Pages: 9 - 9

10. Levetiracetam-related AEs reported to FAERS

    Clinical study 13 April 2024 Pages: 10 - 10

11. Oral contraceptive-related AEs in adolescents

    Clinical study 13 April 2024 Pages: 11 - 11

12. Postoperative tramadol increases all-cause SAEs

    Clinical study 13 April 2024 Pages: 12 - 12

13. Other adverse reaction research

    News item 13 April 2024 Pages: 13 - 13

14. Antineoplastics

    Case report 13 April 2024 Pages: 14 - 14

15. Abdavomeran

    Case report 13 April 2024 Pages: 15 - 15

16. Abemaciclib

    Case report 13 April 2024 Pages: 16 - 16

17. Abiraterone

    Case report 13 April 2024 Pages: 17 - 17

18. Acalabrutinib

    Case report 13 April 2024 Pages: 18 - 18

19. Acetazolamide

    Case report 13 April 2024 Pages: 19 - 19

20. Acetazolamide/dorzolamide

    Case report 13 April 2024 Pages: 20 - 20

21. Acetazolamide/furosemide

    Case report 13 April 2024 Pages: 21 - 21

22. Acetazolamide/ibuprofen

    Case report 13 April 2024 Pages: 22 - 22

23. Acetylcysteine/paracetamol

    Case report 13 April 2024 Pages: 23 - 23

24. Aciclovir

    Case report 13 April 2024 Pages: 24 - 24

25. Ad26.COV2-S

    Case report 13 April 2024 Pages: 25 - 25

26. Ad26.COV2-S/elasomeran/tozinameran

    Case report 13 April 2024 Pages: 26 - 26

27. Adalimumab

    Case report 13 April 2024 Pages: 27 - 27

28. Adalimumab

    Case report 13 April 2024 Pages: 28 - 28

29. Adalimumab/atovaquone/prednisone

    Case report 13 April 2024 Pages: 29 - 29

30. Adalimumab/Golimumab

    Case report 13 April 2024 Pages: 30 - 30

31. Adalimumab/infliximab

    Case report 13 April 2024 Pages: 31 - 31

32. Adenosine

    Case report 13 April 2024 Pages: 32 - 32

33. Adenosine

    Case report 13 April 2024 Pages: 33 - 33

34. Adenosine/doxycycline

    Case report 13 April 2024 Pages: 34 - 34

35. Afatinib

    Case report 13 April 2024 Pages: 35 - 35

36. Afatinib/amivantamab

    Case report 13 April 2024 Pages: 36 - 36

37. Afatinib/crizotinib

    Case report 13 April 2024 Pages: 37 - 37

38. Agalsidase-alfa/rituximab

    Case report 13 April 2024 Pages: 38 - 38

39. Alemtuzumab/cyclophosphamide/pentostatin

    Case report 13 April 2024 Pages: 39 - 39

40. Alemtuzumab/Thiamazole

    Case report 13 April 2024 Pages: 40 - 40

41. Alendronic-acid

    Case report 13 April 2024 Pages: 41 - 41

42. Alendronic-acid/risedronic-acid

    Case report 13 April 2024 Pages: 42 - 42

43. Alitretinoin

    Case report 13 April 2024 Pages: 43 - 43

44. Alpelisib

    Case report 13 April 2024 Pages: 44 - 44

45. Alpha-ketoglutaric-acid/arginine/calcium-beta-hydroxybutyrate/KTX-0101/magnesium-beta-hydroxybutyrate/medium-chain-triglyceride-oil/7-oxo-prasterone

    Case report 13 April 2024 Pages: 45 - 45

46. Alprazolam

    Case report 13 April 2024 Pages: 46 - 46

47. Amantadine/favipiravir/ribavirin

    Case report 13 April 2024 Pages: 47 - 47

48. Amfetamine

    Case report 13 April 2024 Pages: 48 - 48

49. Aminoglycosides/antibacterials/carbapenems

    Case report 13 April 2024 Pages: 49 - 49

50. Amiodarone

    Case report 13 April 2024 Pages: 50 - 50